Pfizer (PFE) Asset Writedowns and Impairment (2009 - 2026)

Pfizer (PFE) has 18 years of Asset Writedowns and Impairment data on file, last reported at $32.0 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment fell 85.71% year-over-year to $32.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$192.0 million (down 132.0% YoY) and the FY2023 annual result came in at $3.0 billion, up 445.45% from the prior year.
• Asset Writedowns and Impairment improved to $32.0 million in Q1 2026 per PFE's latest filing, from -$577.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $2.5 billion in Q4 2023 and bottomed at -$577.0 million in Q4 2025.
• The 5-year median for Asset Writedowns and Impairment is $200.0 million (2022), against an average of $310.0 million.
• The widest annual swing landed in 2023, when Asset Writedowns and Impairment surged 770.97%; it then slumped 85.71% in 2026.
• Tracing PFE's Asset Writedowns and Impairment over 5 years: stood at $200.0 million in 2022, then surged by 1150.5% to $2.5 billion in 2023, then tumbled by 90.4% to $240.0 million in 2024, then slumped by 340.42% to -$577.0 million in 2025, then soared by 105.55% to $32.0 million in 2026.
• Per Business Quant, the three latest PFE Asset Writedowns and Impairment figures stand at $32.0 million (Q1 2026), -$577.0 million (Q4 2025), and $260.0 million (Q3 2025).

Peer Comparison